Key result
Initial high-sensitivity cardiac troponin I demonstrated comparable diagnostic accuracy for NSTE-AMI in patients with and without chronic kidney disease (AUC 0.949 vs 0.937, p=0.783), although specificity was significantly lower in the CKD cohort.
Why the study?
Chronic elevation of cardiac troponin in CKD frequently diminishes its diagnostic utility for evaluating suspected NSTE-AMI, prompting evaluation of initial hs-cTnI performance in patients with and without CKD.
Does initial high-sensitivity cardiac troponin I (hs-cTnI) accurately diagnose non-ST-segment elevation acute myocardial infarction (NSTE-AMI) in emergency department patients with chronic kidney disease compared to those with normal renal function?
Observational (n=640)
No
Does initial high-sensitivity cardiac troponin I (hs-cTnI) accurately diagnose non-ST-segment elevation acute myocardial infarction (NSTE-AMI) in emergency department patients with chronic kidney disease compared to those with normal renal function?
Initial hs-cTnI maintains high overall diagnostic accuracy (AUC 0.949) for NSTE-AMI in patients with chronic kidney disease, and increasing the diagnostic cutoff from the 99th percentile (11 ng/L) to an ROC-optimized threshold (53.4 ng/L) restores specificity from 60.8% to 88.1% while maintaining high negative predictive value (97.2%).
Background: Patients with chronic kidney disease (CKD) exhibit a heightened risk of myocardial infarction. Chronic elevation of cardiac troponin levels frequently occurs in CKD patients, thereby diminishing their diagnostic utility in the evaluation of suspected non-ST-segment elevation acute myocardial infarction (NSTE-AMI). This study aimed to assess the diagnostic performance of initial high-sensitivity cardiac troponin I (hs-cTnI) for AMI in populations with and without chronic kidney disease. Methods: A total of 142 consecutive CKD patients attending the nephrology outpatient clinic were enrolled to investigate the association between baseline hs-cTnI concentrations and estimated glomerular filtration rate (eGFR). In parallel, A total of 237 CKD patients presenting to the emergency department with suspected NSTE-AMI were consecutively recruited, alongside a control group of 261 individuals with normal renal function. Receiver operating characteristic (ROC) curves assessed hs-cTnI diagnostic performance, with subgroup comparisons. Results: CKD patients exhibited significantly higher median hs-cTnI levels which correlated inversely with eGFR (p < 0.001). The incidence of adjudicated NSTE-AMI was higher in the CKD cohort (18.1 % vs. 6.9 % in controls, p < 0.001). Diagnostic accuracy of initial hs-cTnI did not differ significantly between groups, as reflected by comparable AUC values (0.949 in CKD vs. 0.937 in controls, P = 0.783). However, specificity for NSTE-AMI was lower in CKD (60.1 % vs. 90.6 %, p < 0.001), which can be restored by applying a higher cutoff. Conclusions: Despite of reduced specificity in patients with CKD, hs-cTnI continues to be a valuable diagnostic marker. Adopting higher diagnostic thresholds and prospectively validating them may lead to improved diagnostic performance.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted an observational in Suspected non-ST-segment elevation acute myocardial infarction (NSTE-AMI) (n=640). High-sensitivity cardiac troponin I (hs-cTnI) vs. Patients with normal renal function (no CKD) was evaluated on Diagnostic accuracy (AUC) for NSTE-AMI (p=0.783). Initial high-sensitivity cardiac troponin I demonstrated comparable diagnostic accuracy for NSTE-AMI in patients with and without chronic kidney disease (AUC 0.949 vs 0.937, p=0.783), although specificity was significantly lower in the CKD cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: